Insmed Inc INSM

NAS: INSM | ISIN: US4576693075   14/11/2024
71,26 USD (+0,93%)
(+0,93%)   14/11/2024

6 september 2024 · Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

8 augustus 2024 · Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update · Persbericht

2 augustus 2024 · Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

29 juli 2024 · Insmed to Host Second-Quarter 2024 Financial Results Conference Call on Thursday, August 8, 2024 · Persbericht

5 juli 2024 · Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

3 juli 2024 · Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference · Persbericht

27 juni 2024 · Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025 · Persbericht

7 juni 2024 · Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

5 juni 2024 · Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference · Persbericht

30 mei 2024 · Insmed to Host Commercial Webinar on June 4, 2024 · Persbericht

30 mei 2024 · Insmed Announces Pricing of $650 Million Public Offering of Common Stock · Persbericht

29 mei 2024 · Insmed Announces Proposed $500 Million Public Offering of Common Stock · Persbericht

28 mei 2024 · Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis · Persbericht

27 mei 2024 · Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis · Persbericht

20 mei 2024 · Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session · Persbericht

9 mei 2024 · Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update · Persbericht

7 mei 2024 · Insmed To Present at the BofA Securities Health Care Conference 2024 · Persbericht

3 mei 2024 · Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

25 april 2024 · Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024 · Persbericht

5 april 2024 · Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

Mijn selecties